Home › Portfolio Model Subscription › Novavax (NVAX-$218.76, NASDAQ) Covid-19 Vaccine Looks Quite Encouraging: Johnson and Johnson Covid-19 Vaccine (JNJ-$163.55, NYSE), Much Less so.

Novavax (NVAX-$218.76, NASDAQ) Covid-19 Vaccine Looks Quite Encouraging: Johnson and Johnson Covid-19 Vaccine (JNJ-$163.55, NYSE), Much Less so.

Posted on January 29, 2021 by Randolph McDuff — No Comments ↓

https://www.barrons.com/articles/novavax-stock-soars-as-its-covid-19-vaccine-outperforms-j-js-51611930639?siteid=yhoof2

Novavax might be a takeover candidate by one of the large pharma companies, based upon this initial indication.

Posted in Portfolio Model Subscription

Leave a Reply

Recent Comments
    Archives